SavedAdd your journal

Journals / The European Research Journal / 2026 / Volume: 9 Issue: 5

Long-term outcomes of COVID-19 infection in patients with solid tumors

Oktay Ünsal(Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey)0000-0002-3215-8457
Ozan Yazıcı(Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey)0000-0003-2844-0959
Ömer Faruk Özkan(Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey)0000-0002-2006-2642
Gözde Savaş(Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey)0000-0003-2274-6586
Nuriye Yıldırım Özdemir(Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey)0000-0002-9235-9592
Aytuğ Üner(Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey)0000-0003-3836-3854
Nazan Günel(Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey)0000-0003-3152-6008
Ahmet Özet(Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey)0000-0001-8731-9636
Pages
—
Publication Date
2023-09-04
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: The patients with aged ≥ 65 years, diagnosed with lung cancer, receiving active anticancer therapy, with active/stable/progressive and advanced cancer stage were at increased risk of mortality from COVID-19 infection in long-term follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We analyzed the impact of some clinical and disease-specific factors on the longterm outcomes of SARS-CoV-2 infection in patients with solid tumors.
📊
Key Findings & Data:Methods: Total of 739 patients with known solid malignancy and infected by SARS-CoV-2 before the beginning of vaccination were examined.
💡
Conclusion & Impact:Conclusions: The patients with aged ≥ 65 years, diagnosed with lung cancer, receiving active anticancer therapy, with active/stable/progressive and advanced cancer stage were at increased risk of mortality from COVID-19 infection in long-term follow-up.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Cancer patients · COVID-19 · mortality

Abstract

Objectives: We analyzed the impact of some clinical and disease-specific factors on the longterm outcomes of SARS-CoV-2 infection in patients with solid tumors. Methods: Total of 739 patients with known solid malignancy and infected by SARS-CoV-2 before the beginning of vaccination were examined. Results: Seventy-six cancer patients died from COVID-19 infection-related effects such as mostly pulmonary and cardiovascular system disorders after a median 16-month follow-up (67.1% and 14.5%; respectively). Compared with survivors (n = 468), non-survivors due to COVID-19 infection related effects (n = 76) were more likely to be aged ≥ 65 years and diagnosis with lung cancer ( p = 0.01). Also, female patients were at decreased risk of mortality [OR: 0.34 (95% CI: 0.18-0.65)]. Furthermore, patients with tumor stage IV, active/stable/progressive disease and patients receiving active anticancer therapy were at increased risk of mortality ( p = 0.01). Conclusions: The patients with aged ≥ 65 years, diagnosed with lung cancer, receiving active anticancer therapy, with active/stable/progressive and advanced cancer stage were at increased risk of mortality from COVID-19 infection in long-term follow-up.

🔖

Cite This Article

Ünsal, O., Yazıcı, O., Özkan, Ö. F., Savaş, G., Özdemir, N. Y., Üner, A., Günel, N., Özet, A. (2023). Long-term outcomes of COVID-19 infection in patients with solid tumors. The European Research Journal, Volume: 9 Issue: 5. https://doi.org/10.18621/eurj.1251443

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (43)

  1. Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, et al. COVID-19 outcomes among patients with cancer: observations from the University of California Cancer Consortium COVID-19 Project Outcomes Registry. Oncologist 2022;27:398-406.
  2. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol 2020;92:2067-73.
  3. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220-32.
  4. Zarei M, Bose D, Nouri-Vaskeh M, Tajiknia V, Zand R, Ghasemi M. Long-term side effects and lingering symptoms post COVID-19 recovery. Rev Med Virol 2022;32:e2289.
  5. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia 2020;34:1637-45.
  6. Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020;26:1218-23.
  7. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al: Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335-7.
  8. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al: Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020;10:935-41.
  9. Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer an the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020;21:1309-16.
  10. Pinato DJ, Lee AJX, Biello F, Segui E, Aguilar-Company J, Carbó A, et al. Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe. Cancers (Basel) 2020;12:e1841.
  11. Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, et al. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol 2021;22:1669-80.
  12. OnCovid Study Group, Pinato DJ, Patel M, Scotti L, Colomba E, Dolly S, Loizidou A, et al. Time-dependent COVID-19 mortality in patients with cancer: an updated analysis of the OnCovid Registry. JAMA Oncol 2022;8:114-22.
  13. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395:1907-18.
  14. ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la Cámara R, et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 2022;15:45-53.
  15. 15 Barlesi F, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C, et al. Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. Cancer Res 2020;80:CT403.
  16. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al; ISARIC4C investigators. Features of 20 133 UK patients in hospital with Covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ 2020;369:m1985.
  17. Ferrando-Vivas P, Doidge J, Thomas K, Gould DW, Mouncey P, Shankar-Hari M, et al; ICNARC COVID-19 Team. Prognostic factors for 30-day mortality in critically ill patients with Coronavirus Disease 2019: an observational cohort study. Crit Care Med 2021;49:102-11.
  18. Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One 2021;16:e0247461.
  19. Flook M, Jackson C, Vasileiou E, Simpson CR, Muckian MD, Agrawal U, et al. Informing the public health response to COVID-19: a systematic review of risk factors for disease, severity, and mortality. BMC Infect Dis 2021;21:342.
  20. Venkatesulu BP, Chandrasekar VT, Girdhar P, Advani P, Sharma A, Elumalai T, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectr 2021;5:pkaa102.
  21. Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020;26:1218-23.
  22. Özdemir N, Dizdar Ö, Yazıcı O, Aksoy S, Dede DS, Budakoğlu B, et al. Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data. Int J Cancer 2021;148:2407-15.
  23. Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. Biomed Pharmacother 2020;128:110267.
  24. Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the treatment of COVID-19 - preliminary report. Reply. N Engl J Med 2020;383:994.
  25. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382:1787-99.
  26. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021;384:693-704.
  27. World Health Organization. Coronavirus disease (COVID-2019) situation reports. Available from: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/situation reports.
  28. Hijano DR, Maron G, Hayden RT. Respiratory viral infections in patients with cancer or undergoing hematopoietic cell transplant. Front Microbiol 2018;9:3097.
  29. Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol 2009;10:589-97.
  30. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Chen. Clinical characteristics of COVID-19 infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31:894-901.
  31. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Centre for Disease Control and Prevention. JAMA 2020;323:1239-42.
  32. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care 2020;24:179.
  33. Pace Hospitals. Post COVID complications, long term effects of coronavirus after recovery 2021. Available from: https://www.pacehospital.com/post-covid-complications-long-term-effects-of-coronavirus-after-recovery [accessed 24 February 2022].
  34. Healio. Long-term effects of COVID-19 and cancer create population of ‘dual survivors’. Available from: https://www.healio.com/news/hematology-oncology/20210816/long-term-effects-of-covid19-and-cancer-create-population-of-dual-survivors [accessed 24 February 2022].
  35. Healio. Long-term COVID-19 effects impact 15% of patients with cancer, may impair outcomes. Available from: https://www.healio.com/news/hematology-oncology/20210909/long-term-covid19-effects-impact-15-of-patients-with-cancer-may-impair-outcomes [accessed 24 February 2022].
  36. Mauri D, Kamposioras K, Tolia M, Alongi F, Tzachanis D. Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic. Lancet Oncol 2020;21:759-60.
  37. Park MD. Sex differences in immune responses in COVID-19. Nat Rev Immunol 2020; 20:461.
  38. Mauvais-Jarvis F. Aging, male sex, obesity, and metabolic inflammation create the perfect storm for COVID-19. Diabetes 2020;69:1857-63.
  39. Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer 2021;9:e002266.
  40. Passaro A, Peters S, Mok TSK, Attili I, Mitsudomi T, de Marinis F. Testing for COVID-19 in lung cancer patients. Ann Oncol 2020;31:832-4.
  41. Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol 2020;13:75.
  42. Tang LV, Hu Y. Poor clinical outcomes for patients with cancer during the COVID-19 pandemic. Lancet Oncol 2020;21:862-4.
  43. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020;10:783-91.